Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)

Julien Taieb, Simon Pernot, Frédéric Thuillier, Alexis Delattre, Erwan Vo-Quang, Caroline Petorin, Vincent Bourgeois, David Tougeron, Franck Audemar, Carole Vitellius, Laurent Mosser, Jérôme Desrame, Frédéric Di Fiore, Yves Rinaldi, Anna Pellat, Marion Bolliet, Fabienne Watelle, Hervé Perrier, Olivier Dubreuil, Come Lepage, Jean-Baptiste Bachet

Open source

DOI: 10.1016/j.eclinm.2026.103998
Published: 2026-06
Container: eClinicalMedicine
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2026.103998,
  title = {Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)},
  author = {Julien Taieb and Simon Pernot and Frédéric Thuillier and Alexis Delattre and Erwan Vo-Quang and Caroline Petorin and Vincent Bourgeois and David Tougeron and Franck Audemar and Carole Vitellius and Laurent Mosser and Jérôme Desrame and Frédéric Di Fiore and Yves Rinaldi and Anna Pellat and Marion Bolliet and Fabienne Watelle and Hervé Perrier and Olivier Dubreuil and Come Lepage and Jean-Baptiste Bachet},
  year = {2026},
  journal = {eClinicalMedicine},
  doi = {10.1016/j.eclinm.2026.103998},
  url = {https://doi.org/10.1016/j.eclinm.2026.103998}
}

RIS

TY  - JOUR
TI  - Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)
AU  - Julien Taieb
AU  - Simon Pernot
AU  - Frédéric Thuillier
AU  - Alexis Delattre
AU  - Erwan Vo-Quang
AU  - Caroline Petorin
AU  - Vincent Bourgeois
AU  - David Tougeron
AU  - Franck Audemar
AU  - Carole Vitellius
AU  - Laurent Mosser
AU  - Jérôme Desrame
AU  - Frédéric Di Fiore
AU  - Yves Rinaldi
AU  - Anna Pellat
AU  - Marion Bolliet
AU  - Fabienne Watelle
AU  - Hervé Perrier
AU  - Olivier Dubreuil
AU  - Come Lepage
AU  - Jean-Baptiste Bachet
PY  - 2026
JO  - eClinicalMedicine
DO  - 10.1016/j.eclinm.2026.103998
UR  - https://doi.org/10.1016/j.eclinm.2026.103998
ER  -

APA

Taieb, J., Pernot, S., Thuillier, F., Delattre, A., Vo-Quang, E., Petorin, C., Bourgeois, V., Tougeron, D., Audemar, F., Vitellius, C., Mosser, L., Desrame, J., Fiore, F. D., Rinaldi, Y., Pellat, A., Bolliet, M., Watelle, F., Perrier, H., Dubreuil, O., Lepage, C., & Bachet, J. (2026). Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France). eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.103998

Source records

crossref · retrieved 2026-09-26T11:15:01.062Z